On December 11th, Ding Pharmaceutical announced that its first commercialized product in the world was officially launched. It is reported that Lele is the first PARP inhibitor in Hong Kong approved for the maintenance treatment of all patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA mutation.

Previously, Le has been approved in the United States and Europe in March and November 2017 for second-line treatment of ovarian cancer. On October 22 this year, Lele was approved in Hong Kong. According to public information, the approval of Le Hong in Hong Kong is based on the results of the international Phase III clinical trial ENGOT-OV16/NOVA, which was initiated by TESARO and conducted in a double-blind, placebo-controlled manner.

Ovarian cancer is one of the common gynecological malignancies. According to the data presented in the Big Data Study of Ovarian Cancer, ovarian cancer ranks third in the global incidence rate, with the highest mortality rate. Another researchers estimate that there are about 5.1 new cases of ovarian cancer in China each year, and about 23,000 deaths. Clinical studies have shown that as the first PARP inhibitor approved in Hong Kong for maintenance of all platinum-sensitive recurrent ovarian cancer patients without the need for BRCA or other biomarker testing prior to administration, Le can significantly prolong the median of patients. Progression free survival (PFS).

In 2014, Ding Ding Pharmaceutical was established in Shanghai and is an innovative biopharmaceutical company. At present, Ding Ding Pharmaceutical focuses on drug development in the fields of cancer, autoimmune diseases and infectious diseases. It has three products approved by the US Food and Drug Administration (FDA) and five products that are already in clinical development. The pipelines and anticancer drugs in the research pipeline cover multiple tumor indications such as breast cancer, ovarian cancer, lung cancer, liver cancer and stomach cancer.

In September 2017, Ding Ding Pharmaceutical, which was established only three years ago, was listed on NASDAQ in the United States, making it the first company in the Chinese pharmaceutical industry to market at a market value of more than $1 billion before generating sales revenue. Du Ying, CEO of Ding Pharmaceutical, said that the rapid development of Ding Ding is inseparable from the research and development model of “inside R&D + external cooperation”.

As we all know, long-term, high-input, high-risk is a common problem faced by new drug research and development companies. “In-house R&D + External Cooperation” is a relatively new R&D model. Through the synergy of internal and external synergies, on the one hand, it reduces the risk of failure of new drug research and development, on the other hand, it shortens the research and development cycle.

In addition to the impetus of the model, capital forces also play a pivotal role in biopharmaceutical companies. At this point, Ding Ding is no exception. According to the data collected by Tianyue, before the IPO, Ding Pharmaceutical received three rounds of financing from A, B and C, and the total financing amounted to approximately US$166 million. In September 2018, Ding Ding was awarded a strategic investment in NVCR.

Today, Ding Ding has established a global R&D center in Shanghai, focusing on independent research and development of innovative drugs. At the same time, it has also built a small molecule and macromolecular production base in Suzhou to empower the future independent production. In addition, in order to promote the clinical application of the music, Ding Pharmaceutical established a business and medical team in Hong Kong. According to Du Ying, it is planned to be listed in mainland China in 2020.

Bifidobacterium Bifidum

Bifidobacterium Bifidum,Bifidobacterium Bifidum Powder,Bifidobacterium Bifidum Probiotic,Bifidobacterium Bifidum Supplements

Biodep Biotechnology Co. ,Ltd. , https://www.biodep.com